ECONOMIC EVALUATION OF MELOXICAM (7.5 MG) VERSUS SUSTAINED RELEASE DICLOFENAC (100 MG) TREATMENT FOR OSTEOARTHRITIS : A CROSS-NATIONAL ASSESSMENT FOR FRANCE, ITALY AND THE UK